Saturday, February 21, 2026
- Home
- NewsService
Author
NewsService
News Service
BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
Wed, Oct 19, 2022 06:15 ET
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
Wed, Oct 19, 2022 05:15 ET
